Takeda's Diabetes Drug Gets U.S. Approval
Posted on: Tuesday, 30 August 2005, 18:01 CDT
Tokyo, Aug. 30 (Jiji Press)--Takeda Pharmaceutical Co. said Tuesday it has obtained approval by the U.S. Food and Drug Administration to market a tablet drug for type 2 diabetes.
The Japanese drug maker will start selling the drug, Actoplus Met, in the United States in October through its subsidiary Takeda Pharmaceuticals North America Inc., it said.
Actoplus Met combines pioglitazone and metformin, two widely used diabetes medications, in a single tablet. Pioglitazone, already marketed as Actos by Takeda, directly targets insulin resistance, while metformin reduces the amount of glucose produced by the liver.
The two substances work in combination to help patients with type 2 diabetes, a leading lifestyle disease, manage their plasma glucose levels, the company said.END
Source: Jiji Press English News Service
Related Articles
- Diabetes Diagnosis, Treatment and Drug Delivery Market will Almost Triple in Value by 2016, Says iData Research
- Takeda Files NDA for Actos OD Tablets in Japan
- Study: Statins Help Diabetics
- Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
- Takeda Given EU Marketing Approval for Diabetes Drug
- Actos Cuts Heart Risk in Diabetics, Takeda
- Japan's Largest Drug Maker Takeda Aloof on Domestic Mergers
- Takeda on track to release pill for Alzheimer's
- New Insomnia Drug Shows Promise
- Study Warns of Drugs' Diabetes Risk
 |
 |
User Comments (0)
RSS Feeds